Evidence map›Paper›PMID 41951275›Full record

ArticleJHEP reports : innovation in hepatology2026

Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies.

Pierre Nahon, Richard Layese, Pierre-André Natella, Lucia Parlati, Tounes Saidi, Nathalie Ganne-Carrié, Gisèle N'Kontchou, Cendrine Chaffaut, Jean-Charles Nault, Jessica Bamba-Funck and 5 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pierre NahonAP-HP, Hôpitaux Universitaires Paris Seine Saint-Denis, APHP, Liver Unit, Université Sorbonne Paris Nord, F-93000 Bobigny, Inserm, UMR-1138 "Functional Genomics of Solid Tumors", Centre de recherche des Cordeliers, Université de Paris, Paris, France. Electronic address: pierre.nahon@aphp.fr.
Richard LayeseUniv Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Unité de Recherche Clinique (URC Mondor), Service de Santé Publique, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94000, Créteil, France.
Pierre-André NatellaUniv Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Unité de Recherche Clinique (URC Mondor), Service de Santé Publique, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94000, Créteil, France.
Lucia ParlatiUniversité de Paris, département d'hépatologie/Addictologie, Hôpital Cochin, APHP, Paris, France.
Tounes SaidiClinical Research Department, ANRS | Emerging Infectious Diseases, Paris, France.
Nathalie Ganne-CarriéAP-HP, Hôpitaux Universitaires Paris Seine Saint-Denis, APHP, Liver Unit, Université Sorbonne Paris Nord, F-93000 Bobigny, Inserm, UMR-1138 "Functional Genomics of Solid Tumors", Centre de recherche des Cordeliers, Université de Paris, Paris, France.
Gisèle N'KontchouAP-HP, Hôpitaux Universitaires Paris Seine Saint-Denis, APHP, Liver Unit, Université Sorbonne Paris Nord, F-93000 Bobigny, Inserm, UMR-1138 "Functional Genomics of Solid Tumors", Centre de recherche des Cordeliers, Université de Paris, Paris, France.
Cendrine ChaffautSBIM, APHP, Hôpital Saint-Louis, Paris, Inserm, UMR-1153, ECSTRA Team, Paris, France.
Jean-Charles NaultAP-HP, Hôpitaux Universitaires Paris Seine Saint-Denis, APHP, Liver Unit, Université Sorbonne Paris Nord, F-93000 Bobigny, Inserm, UMR-1138 "Functional Genomics of Solid Tumors", Centre de recherche des Cordeliers, Université de Paris, Paris, France.
Jessica Bamba-FunckUniversité Sorbonne Paris Nord, Laboratory for Vascular Translational Science, LVTS, INSERM, UMR 1148, F-93430, Villetaneuse, Université de Paris, F-75018, Paris, AP-HP, HUPSSD, Hôpital Avicenne, Laboratoire de Biochimie, F-93000, Bobigny, France.
Angela SuttonUniversité Sorbonne Paris Nord, Laboratory for Vascular Translational Science, LVTS, INSERM, UMR 1148, F-93430, Villetaneuse, Université de Paris, F-75018, Paris, AP-HP, HUPSSD, Hôpital Avicenne, Laboratoire de Biochimie, F-93000, Bobigny, France.
Clovis Lusivika NzingaSorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, France.
Fabrice CarratSorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, France.
Etienne AudureauUniv Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Unité de Recherche Clinique (URC Mondor), Service de Santé Publique, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94000, Créteil, France.
ANRS CO12 CirVir, ANRS CO22 Hepather, and CIRRAL groups

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsWe aimed to develop machine learning (ML) models for hepatocellular carcinoma (HCC) risk stratification in patients with cirrhosis and to test their ability to identify those with an annual HCC incidence >3%, for whom more intensive surveillance may be justified.

methodsData from three prospective cohorts (ANRS CO12 CirVir, CO22 Hepather, APHP CIRRAL) were analyzed. All patients underwent semiannual ultrasound surveillance and were randomly split into training and validation sets. HCC incidence was evaluated using a competing risk framework. A single tree (ST) model was developed using conditional decision trees, while random forest (RF) models were built by aggregating 1,000 trees. A deep neural network (DNN)-based survival model was also applied. ML model performance was compared with established regression-based scores: aMAP (age-male-ALBI-platelets) and FASTRAK (FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer).

resultsAmong 4,867 patients with non-viral cirrhosis or resolved/controlled viral cirrhosis, 294 (9.2%) developed HCC over a median follow-up of 61.5 months (annual incidence: 1.99%). The ST model identified four key predictors, generating five distinct risk groups. These included patients with mildly impaired liver function or those with elevated GGT and low platelet counts. The RF and DNN approaches confirmed ST findings and delineated complex interactions among predictors. Performance metrics (C-index, Brier score, decision curve analysis) showed no significant advantage of ML models over aMAP and FASTRAK. Calibration was consistent across models. ML models identified higher proportions of patients with an annual HCC incidence >3% (ST 44%; DNN 37%; RF 30%) compared with aMAP (36%) and FASTRAK (29%).

conclusionsML-based algorithms did not outperform traditional risk scores but provided novel insights into variable interactions and helped identify clinically relevant patient subgroups with differing HCC risk profiles. IMPACT AND IMPLICATIONS: Accurate stratification of hepatocellular carcinoma risk in cirrhosis is essential to optimize surveillance strategies, and this study provides a scientific rationale for exploring machine learning approaches to capture complex, non-linear interactions among clinical variables beyond traditional regression models. Although machine learning did not improve predictive performance over established scores, it revealed clinically meaningful risk subgroups defined by liver function, platelet count, and GGT, underscoring its value as an interpretative and hypothesis-generating tool. These results are particularly relevant for hepatologists and clinical researchers seeking to refine risk-adapted surveillance and to inform the design of future models or trials.

Indexed as

cirrhosiscost-effectivenessHCC risk stratificationmachine learningsurveillance

Identifiers

PMID41951275
PMCPMC12972975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.